

Deaf





Overview

COPD

Key Details

Eligibility

Participation

Benefits

# Overview

## Are you one of the millions of Americans suffering from COPD?

**The AERIFY studies are exploring a new investigational medication for individuals with COPD.**

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that makes it hard to breathe, usually caused by exposure to noxious particles or gases like cigarette smoke. While there are medications available to treat symptoms, many people still struggle to achieve symptom relief.

This is a clinical research study to investigate the safety and efficacy of an innovative treatment option in reducing COPD flares (exacerbations) in patients struggling with persistent moderate-to-severe COPD symptoms.

The purpose of the AERIFY studies are to evaluate the safety and effectiveness of Itepekimab for moderate-to-severe COPD in patients aged 40-85.

Brought to you by:




Powered by:

**TrialSpark**

# COPD

## What is COPD?

Chronic obstructive pulmonary disease (COPD) is a lung disease that makes it hard to breathe. In people with COPD, the airways (the branching tubes that carry air within the lungs), become narrow and damaged. This makes people feel out of breath and tired.



The most common cause of COPD is smoking. Smoke can damage the lungs permanently and cause COPD. People can also get COPD from breathing in toxic fumes or gases. In rare cases, COPD is caused by a genetic problem.



# Key Details

## Key Trial Details



For the AERIFY-1 study, which only includes former smokers, patients have a 2:1 chance of receiving the investigational product (IP) vs. the placebo.



For the AERIFY-2 study, which includes current and former smokers, former smokers have a 2:1 chance of receiving the IP vs. the placebo while current smokers have a 1:1 chance of receiving the IP vs. the placebo.



The placebo is a treatment that doesn't have any active medical ingredients. Neither the study staff nor you will know which group you are in. However, in case of an emergency the doctor can quickly find out.



The investigational treatment or placebo will be in the form of an injection taken every other week over a 52-week treatment period.



This study will be conducted under the supervision of a licensed doctor. Participation is voluntary, and you have the option to stop at any time.

# Eligibility

## Eligibility Requirements

An eligible participant for this study must:

- ✓ Be 40-85 years old
- ✓ Have been diagnosed with COPD by a medical professional
- ✓ Be a former smoker (AERIFY-1 or AERIFY-2) or a current smoker (AERIFY-2 only)
- ✓ Be currently taking medications for COPD
- ✓ Have had 1+ flare-ups in the last year requiring additional treatment and/or medical attention
- ✓ Have chronic bronchitis (a cough with phlegm for 3 months in the past year)

Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in the study and receiving any investigational medication. Not all individuals will qualify to participate.

# Participation

## What does participation look like?

**Participation in the study will last approximately 77 weeks in total and consists of three parts:**



### **Screening (3-5 weeks)**

If interested in the study, you will be asked to review and sign a consent form to make an educated decision about whether to participate in the trial. Once signed, the study doctor will perform assessments to confirm that you are eligible to participate.



### **Treatment (52 weeks)**

The study medication is an injection taken every other week that potentially reduces inflammation in the lungs. To monitor safety and study progress, certain study visits will include: history and physical exam, spirometry testing, injection of study medication (Itepekimab), electrocardiogram (EKG), blood tests, and questionnaires.



### **Follow-up (20 weeks)**

After treatment ends, the study doctor will continue to follow up with you to thoroughly monitor and evaluate patient safety.

# Benefits

## Benefits of Participating

COPD is a chronic condition that can be difficult to control, and can have a negative impact on quality of life.

### **Some potential benefits from participating:**

- ✓ Access an investigational treatment that may help reduce moderate-to-severe symptom flare-ups.
- ✓ Help advance COPD research. The information and knowledge gained from this study could help others suffering from COPD in the future.
- ✓ All study related medications, analysis, clinic visits, and procedures will be provided at no cost. Additionally, trial participants will be eligible to receive vouchers to cover the cost of their current approved COPD medications.

Participation is 100% optional and the clinical research study team will discuss all benefits and risks with you in more detail.



# More information

For more information, please visit:

**[trials.spark.com/trial/copd](https://trials.spark.com/trial/copd)**

